China's pharma market boom: over 650% revenue growth by 2020

25 July 2013

Considerable investment in China’s pharmaceutical R&D sector, along with numerous government-initiated reforms, will spark soaring growth in the country’s pharmaceutical market in the near future, says a new report from research and consulting firm GlobalData.

According to the company’s latest report on China’s healthcare industry, the country’s pharmaceutical market value will climb from an estimated $48 billion in 2012 to a massive $315 billion in 2020, growing at a compound annual growth rate (CAGR) of 26.5%.

Will become second largest pharma market

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical